Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT)

Vancouver, British Columbia, March 16, 2026 -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) is pleased to announce the commencement of its commercial phased rollout of the Marijuana Breath Test (“MBT”) system. This phase includes the delivery of MBT units to select commercial customers across multiple industries, followed by a planned scale‑up in production.

The Marijuana Breath Test fills a critical gap and delivers new technology and methods that provide a complete, non‑invasive solution for detecting recent cannabis use, specifically delta‑9 THC (the primary psychoactive compound in cannabis) in breath, within approximately 4 hours of consumption at levels above 5 pg/L. This capability addresses a long‑standing need among employers, law enforcement agencies, and safety‑sensitive industries, which have historically relied on testing methods that detect primarily past cannabis use. As legalized recreational and medical marijuana use continues to expand across the United States and globally, accurate detection of recent use via breath is becoming essential for maintaining fairness, relevance, and informed decision‑making.

n early March 2026, an independent peer‑reviewed publication in the Journal of Analytical Toxicology (JAT) became publicly available confirming the ability of the MBT system to detect delta‑9 THC.

Over recent months, Cannabix and its partners have completed many initiatives to enable the commercial rollout of the MBT system:

• Key enhancements to the Breath Collection Unit (BCU) and Breath Cartridges (Figures 1 and 2), along with the initial validation package prepared by Omega Laboratories (“Omega”).
• Integration of Cannabix Breath Cartridges into Omega’s operational workflows, including chain‑of‑custody processes and electronic reporting through its Laboratory Information Management System (LIMS).
• Established manufacturing procedures and partnerships, standard operating procedures, and QA/QC processes for MBT hardware.
• BCU successfully passing FCC electronic emissions testing.
• The MBT system will follow a recurring revenue model in which the handheld BCU serves as the required hardware for all deployments, while disposable Breath Cartridges generate ongoing revenue as they are used for every test performed.
• Pre‑launch marketing initiatives conducted with Omega (Ohio) and AlcoPro (Knoxville, TN).
• Preparation of end‑user training materials, logistics planning, and customer support resources.
• Release of peer‑reviewed Journal of Analytical Toxicology publication, titled: “Simultaneous Analysis of Δ9‑THC, Δ8‑THC, CBD, and CBN in Breath Aerosols Collected Using Cannabix Technologies Breath Collection Unit.” (March 2026) link: https://doi.org/10.1093/jat/bkag016

The MBT platform consists of the Cannabix Breath Collection Unit (BCU), disposable Breath Cartridges, and the Laboratory‑Developed Test Method by Omega Laboratories. Cannabix has a strategic partnership with Omega Laboratories Inc, a global leader in forensic drug testing for over 25 years. Omega holds multiple federal and international certifications and operates a world-class facility with extensive experience in novel drug detection technologies.

Why Recent Use Detection of Cannabis Is Important

Traditional cannabis testing methods such as urine, saliva, or hair analysis, primarily detect historical cannabis use. These methods can return positive results hours, days, or even weeks after consumption, making them ineffective for determining whether an individual may be using during the workday.

Scientific research shows that delta‑9 THC is detectable in breath for a short window of approximately 2–4 hours, closely aligned with the period of peak impairment. Breath analysis therefore provides the most relevant and scientifically meaningful indication of recent use, which is the metric employers and safety‑sensitive industries require.